Although tobacco undoubtedly contributes to this increase, Japan has done little to respond to this growing problem, and as a result lung cancer and other tobacco-related diseases are on the rise.

JPMorgan's assessment indicates that Japan Tobacco's shares do not show signs of being particularly undervalued when evaluated against dividend yield or price-to-earnings (P/E) ratio metrics.

Japan Tobacco started 2025 with another quarter of strong results. Tobacco core revenue grew 14% in constant currency as the Vector acquisition and higher pricing offset a 1.3% volume decline in ...